knowledge -WSS

knowledge

author：explore 2025-09-30 19:25:25 - browse：18

intarcia implant. -- health tech coverage from STAT — The matchstick-sized, implantable device from Intarcia Therapeutics releases a steady, continuous, and low-dose stream of a drug for diabetes. Stuart Isett/Fortune Brainstorm Health

An advisory panel to the Food and Drug Administration unanimously voted against a diabetes implant from Intarcia Therapeutics — a former biotech unicorn that faltered after the FDA rejected said implant not once, but twice.

Intarcia called for the panel meeting because of those two rejections, seeking outside input on the FDA’s decision. FDA then granted Intarcia’s request. The agency is not bound to advisory panel decisions, though it tends to follow their advice.

Intarcia started developing its lead therapy, a small, skinny bar implanted under the skin, for type 2 diabetes patients in 2016. The implant delivers a glucose-controlling medicine called exenatide, a member of the GLP-1 drugs that have taken the diabetes and obesity markets by storm. Intarcia’s implant continuously administers the drug over six months, with the goal of improving patient adherence compared to Eli Lilly and Novo Nordisk’s weekly GLP-1 shots.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Congress extends some pandemic preparedness programs

WSS

Acelyrin, a rare IPO success, stumbles in its first big test

Some top drug companies are starting to take action on climate

Will an HIV vaccine ever be a reality?

6 solutions to address cancer drug shortages and others

Experts study whether long Covid risk adds up with each reinfection

What we owe ALS patients — and why one company fell short

focus

knowledge

focus

How one medical school became remarkably diverse

Will an HIV vaccine ever be a reality?

New air purifier tech could be key to improving indoor air quality

Nobel honors Karikó and Weissman's enduring partnership

FDA approval of Sarepta Duchenne genetic therapy gives me hope

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Tori Bowie and the unacceptable rates of Black maternal death

Popular nasal decongestant doesn't actually relieve congestion

Guidelines to prevent youth baseball injuries need more muscle

New Covid vaccine is recommended for everyone 6 months or older

entertainment

Private equity could exacerbate cardiology's overuse problem, experts fear

FDA proposes changes to key medical devices approval pathway

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Food makers tried to stack nutrition panel with preferred experts

Some top drug companies are starting to take action on climate

CRISPR base editing slashes cholesterol levels in monkeys

hotspot

explore

leisure time

knowledge